ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences
May 15, 2025 – BioManufacturing, Drug Discovery, Other, Pharmaceutical – ASGCT 2025, ProQR Therapeutics, RNA, RNA editing technology platform, TIDES USA 2025, cell and gene therapies, conferences and events
12 May 2025 — Leiden, the Netherlands and Massachusetts, US — ProQR Therapeutics NV (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will present at two upcoming scientific conferences: the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, taking place May 13-17, 2025, in New Orleans, Louisiana and the TIDES USA 2025: Oligonucleotide and Peptide Therapeutics Conference, being held May 19-22, 2025, in San Diego, California.
“We are excited to share these presentations with the scientific community, demonstrating the breadth and versatility of our Axiomer RNA editing technology,” said Gerard Platenburg, Chief Scientific Officer of ProQR. “The data we will present at ASGCT and TIDES further support our vision of building a differentiated and diversified pipeline and advancing RNA editing therapies that could offer transformative benefits for patients.”
These presentations will highlight the Company’s proprietary Axiomer RNA editing platform and pipeline programs. Details of ProQR’s presentations are as follows:
American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
May 13-17, 2025 | New Orleans, Louisiana, USA
Oral Presentation
- Title: ADAR-Mediated RNA Editing of SLC10A1(NTCP) as a Therapeutic Approach to Reduce Liver Bile Acid Re-Uptake in Cholestatic Diseases (abstract 333)
- Presenter: Gerard Platenburg, Chief Scientific Officer
- Date/Time: May 16, 2025, 4:15 PM CT
- Session: Oligonucleotide Therapeutics II
Poster Presentations
- Title: ADAR-Mediated RNA Editing-Based Correction of PNPLA3 I148M Functionality to Address Hepatic Steatosis (abstract 1654)
- Presenter: Gerard Platenburg, Chief Scientific Officer
- Date/Time: May 15, 2025, 5:30-7:00 PM CT
- Poster Number: AMA1324
- Title: ADAR-Mediated RNA Editing of Premature Termination Codon Results in Functional Correction in MECP2 for Rett Syndrome (abstract 1645)
- Presenter: Gerard Platenburg, Chief Scientific Officer
- Date/Time: May 15, 2025, 5:30-7:00 PM CT
- Poster Number: AMA1427
TIDES USA: Oligonucleotide and Peptide Therapeutics Conference
May 19-22, 2025 | San Diego, California, USA
Podium Presentation
- Title: Advancing Axiomer ADAR RNA Editing Platform – Editing oligonucleotides optimization for therapeutic use
- Presenter: Peter A. Beal, PhD, Chief ADAR Scientist
- Date/Time: May 22, 2025, 2:00 PM PST
- Session/Track: Genome Editing Technology and Applications
Following the conferences, presentation materials will be made available in the Publications and Presentations section of the ProQR website at www.proqr.com.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. Learn more about ProQR at www.proqr.com.
